Digital brain biomarker company Monument Therapeutics raises £2.6 million
Drug Discovery Today
JULY 7, 2021
Cambridge Cognition spin-out targets schizophrenia and post-operative cognitive dysfunction
Sat.Jul 03, 2021 - Fri.Jul 09, 2021
113 
Which pharmaceutical companies have the most drug patents in Poland?
Drug Patent Watch
JULY 9, 2021
This chart shows the pharmaceutical companies with the most patents in Poland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Poland? appeared first on DrugPatentWatch - Make Better Decisions.
WORLD’S LARGEST BROWSABLE RESOURCE LINKING RARE PROTEIN-CODING GENETIC VARIANTS TO HUMAN HEALTH AND DISEASE
The Pharma Data
JULY 8, 2021
Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants.
Importance of FDA Combination Products
Pharmaceutical Development Group
JULY 7, 2021
Introduction FDA (can also be expanded as the Food and Drug Administration) is a bureau that administers the public’s welfare by controlling and surveillance of food products, medications, vaccines, medical devices, etc. There are certain rules and criteria for post marketing safety reporting of FDA combination products. What are combination products?
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The Current issue of “The view from here” is concerned with Cardiovascular Drugs
Drug Discovery Today
JULY 8, 2021
The topic of this month’s newsletter from Drug Discovery Today is “Cardiovascular Drugs”.
New patent for Optinose Us drug XHANCE
Drug Patent Watch
JULY 7, 2021
Annual Drug Patent Expirations for XHANCE Xhance is a drug marketed by Optinose Us Inc and is included in one NDA. There are thirteen patents protecting this drug. XHANCE drug…. The post New patent for Optinose Us drug XHANCE appeared first on DrugPatentWatch - Make Better Decisions.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
More Trending
Understanding The Signs & Symptoms Of Social Anxiety
Olympian Clinical Research
JULY 7, 2021
Social anxiety disorder, sometimes referred to as a social phobia, is a type of anxiety disorder characterized by extreme fear, distress, and anxiety in social settings. It’s important to note that being naturally more shy, reserved, or introverted is not the same thing as having social anxiety. While people with social anxiety may or may not exhibit shyness in social situations, it’s the uncontrollable fear, anxiety, and subsequent avoidance of social situations that differentiates someone with
Preclinical Models for Bispecific T Cell Engager Development
Crown Bioscience
JULY 5, 2021
Last month we hosted a webinar with Dr. Ludovic Bourré, Senior Director of Scientific Engagement at Crown Bioscience, focused on the next generation of preclinical models advancing bispecific T cell engager (BiTE) development.
New patent expiration for Astellas drug MYCAMINE
Drug Patent Watch
JULY 7, 2021
Annual Drug Patent Expirations for MYCAMINE Mycamine is a drug marketed by Astellas and is included in one NDA. It is available from one supplier. There is one patent protecting…. The post New patent expiration for Astellas drug MYCAMINE appeared first on DrugPatentWatch - Make Better Decisions.
FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
The Pharma Data
JULY 8, 2021
ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia. Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced the U.S. Food and Drug Administration (FDA) has approved an updated label for ADUHELM (aducanumab-avwa) injection 100 mg/mL solution. The update includes an addition to the Indications and Usage section of the label (Section 1) to emphasize the disease stages studied in the clinical trials, as seen
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Rite Aid’s PBM Strategy: Will Hope Triumph Over Experience?
Drug Channels
JULY 7, 2021
ICYMI, Rite Aid recently released the financial results for its most recent fiscal quarter, which ended on May 29. Rite Aid’s pharmacy benefit manager (PBM) business, Elixir, continues to flail in an increasingly challenging market. I’ve long been skeptical of Rite Aid’s PBM strategy. As you will see below, last quarter’s results further validated my skepticism.
Automatic Analog Generation With Common R-group Replacements
Practical Cheminformatics
JULY 7, 2021
Another pointer to the FastPages site
New patent expiration for Sucampo Pharma drug RESCULA
Drug Patent Watch
JULY 8, 2021
Annual Drug Patent Expirations for RESCULA Rescula is a drug marketed by Sucampo Pharma Llc and is included in one NDA. There is one patent protecting this drug and one…. The post New patent expiration for Sucampo Pharma drug RESCULA appeared first on DrugPatentWatch - Make Better Decisions.
mRNA vaccines slash risk of COVID-19 infection by 91% in fully vaccinated people
The Pharma Data
JULY 8, 2021
People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of eight sites, including Salt Lake City. For those few vaccinated people who do still get an infection, or “breakthrough” cases, the study suggests that vaccines reduce the severity of COVID-19 symptoms and shorten its duration.
Deliver Fast, Flexible Clinical Trial Insights with Spotfire
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
New patent expiration for Allergan drug ALPHAGAN P
Drug Patent Watch
JULY 9, 2021
Annual Drug Patent Expirations for ALPHAGAN+P Alphagan P is a drug marketed by Allergan and is included in two NDAs. It is available from one supplier. There are eight patents…. The post New patent expiration for Allergan drug ALPHAGAN P appeared first on DrugPatentWatch - Make Better Decisions.
New patent expiration for Astrazeneca drug BRILINTA
Drug Patent Watch
JULY 8, 2021
Annual Drug Patent Expirations for BRILINTA Brilinta is a drug marketed by Astrazeneca and is included in one NDA. It is available from two suppliers. There are four patents protecting…. The post New patent expiration for Astrazeneca drug BRILINTA appeared first on DrugPatentWatch - Make Better Decisions.
New patent expiration for Astrazeneca drug FASLODEX
Drug Patent Watch
JULY 8, 2021
Annual Drug Patent Expirations for FASLODEX Faslodex is a drug marketed by Astrazeneca and is included in one NDA. It is available from one supplier. There are four patents protecting…. The post New patent expiration for Astrazeneca drug FASLODEX appeared first on DrugPatentWatch - Make Better Decisions.
Which pharmaceutical drugs have the most drug patents in Greece?
Drug Patent Watch
JULY 8, 2021
This chart shows the drugs with the most patents in Greece. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Greece? appeared first on DrugPatentWatch - Make Better Decisions.
Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
New patent expiration for Nabriva drug XENLETA
Drug Patent Watch
JULY 8, 2021
Annual Drug Patent Expirations for XENLETA Xenleta is a drug marketed by Nabriva and is included in two NDAs. There are four patents protecting this drug. Drug patent litigation for…. The post New patent expiration for Nabriva drug XENLETA appeared first on DrugPatentWatch - Make Better Decisions.
New patent for Myovant Sciences drug MYFEMBREE
Drug Patent Watch
JULY 8, 2021
Annual Drug Patent Expirations for MYFEMBREE Myfembree is a drug marketed by Myovant Sciences and is included in one NDA. The generic ingredient in MYFEMBREE is estradiol; norethindrone acetate; relugolix.…. The post New patent for Myovant Sciences drug MYFEMBREE appeared first on DrugPatentWatch - Make Better Decisions.
New patent for Arbor Pharms drug EVEKEO ODT
Drug Patent Watch
JULY 8, 2021
Annual Drug Patent Expirations for EVEKEO+ODT Evekeo Odt is a drug marketed by Arbor Pharms Llc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Arbor Pharms drug EVEKEO ODT appeared first on DrugPatentWatch - Make Better Decisions.
Positive new data for Johnson & Johnson single-shot COVID-19 vaccine on activity against Delta variant and long-lasting durability of response
The Pharma Data
JULY 8, 2021
Johnson & Johnson (NYSE: JNJ) (the Company) announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date.
Notice Concerning Issuance of New Shares under the Long-Term Incentive Plan for Company Group Employees Overseas
The Pharma Data
JULY 8, 2021
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Company”) today announced that it decided to issue new shares (“Issuance of New Shares”) under the Long Term Incentive Plan (“LTIP”) for the Company Group employees overseas, as outlined below. Outline of issuance (1) Payment dateJuly 26, 2021(2) Type and number of shares to be issuedShares of common stock in the Company; numbering 3,874,305 shares(3) Issuance price3,685 yen per share(4) Total value of shar
AbbVie to Host Second-Quarter 2021 Earnings Conference Call
The Pharma Data
JULY 8, 2021
AbbVie (NYSE: ABBV) will announce its second-quarter 2021 financial results on Friday, July 30, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.
Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
The Pharma Data
JULY 8, 2021
– The EMPEROR-Preserved phase III trial met its primary endpoint and demonstrated significant risk reduction with Jardiance for the composite of cardiovascular death or hospitalization for heart failure in adults with heart failure with preserved ejection fraction – Heart failure with preserved ejection fraction has been classified as “the single largest unmet need in cardiovascular medicine”¹ based on prevalence, poor outcomes and absence of clinically proven therapies t
Which pharmaceutical companies have the most insert dosed drugs?
Drug Patent Watch
JULY 7, 2021
This chart shows the pharmaceutical companies with the most insert dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most insert dosed drugs…. The post Which pharmaceutical companies have the most insert dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Which pharmaceutical drugs have the most drug patents in Eurasian Patent Organization?
Drug Patent Watch
JULY 6, 2021
This chart shows the drugs with the most patents in Eurasian Patent Organization. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical drugs have the most drug patents in Eurasian Patent Organization? appeared first on DrugPatentWatch - Make Better Decisions.
New patent for DUSA drug LEVULAN
Drug Patent Watch
JULY 6, 2021
Annual Drug Patent Expirations for LEVULAN Levulan is a drug marketed by Dusa and is included in one NDA. It is available from one supplier. There is one patent protecting…. The post New patent for DUSA drug LEVULAN appeared first on DrugPatentWatch - Make Better Decisions.
New patent for Braintree Labs drug SUTAB (COPACKAGED)
Drug Patent Watch
JULY 6, 2021
Annual Drug Patent Expirations for SUTAB+%28COPACKAGED%29 Sutab (copackaged) is a drug marketed by Braintree Labs and is included in one NDA. It is available from one supplier. There is one…. The post New patent for Braintree Labs drug SUTAB (COPACKAGED) appeared first on DrugPatentWatch - Make Better Decisions.
New patent for APGDI drug MYRBETRIQ GRANULES
Drug Patent Watch
JULY 6, 2021
Annual Drug Patent Expirations for MYRBETRIQ+GRANULES Myrbetriq Granules is a drug marketed by Apgdi and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent for APGDI drug MYRBETRIQ GRANULES appeared first on DrugPatentWatch - Make Better Decisions.
Researchers find potential path to a broadly protective COVID-19 vaccine using T cells
The Pharma Data
JULY 6, 2021
Gaurav Gaiha, MD, DPhil, a member of the Ragon Institute of MGH, MIT and Harvard, studies HIV, one of the fastest-mutating viruses known to humankind. But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, piece
Cancer cells eat themselves to survive
The Pharma Data
JULY 6, 2021
It is the membrane of cancer cells that is at the focus of the new research now showing a completely new way in which cancer cells can repair the damage that can otherwise kill them. In both normal cells and cancer cells, the cell membrane acts as the skin of the cells. And damage to the membrane can be life threatening. The interior of cells is fluid, and if a hole is made in the membrane, the cell simply floats out and dies – a bit like a hole in a water balloon.
Elliott Advisors (UK) letter to GSK
The Pharma Data
JULY 6, 2021
The Board of GSK notes the letter issued by Elliott Advisors (UK) Limited (“Elliott”) on 1 July. The Board welcomes constructive input from all shareholders that is supportive of the creation and delivery of long-term sustainable shareholder value and benefits for patients. The Board is issuing this announcement to all shareholders and all parties with an interest in GSK to address the matters raised by Elliott in the letter.
Let's personalize your content